Menu
Menu
Fepod
Measuring the real blood concentration of pain medicine directly from a drop of blood at the point-of-care.
- Healthtech
- Series A
Location
Helsinki, Finland
Revenue size
0 (pre-revenue)
Year founded
2022
Funding raised
EUR 850,000
Founders
Jussi Pyysalo, Niklas Wester, Elsi Verrinder, Antti Rasi & Mikko Laitila
Most relevant investors
Almaral Oy, Dealia Oy & Business Finland
Team size
5+1
Problem
Analyzing the real blood concentration of opioids and painkillers is a slow and expensive process, yet fast results are often urgently needed at the point-of-care.
SOLUTION
Fepod provides a fast, simple and relatively painless sampling process with quick test results, using a mobile phone, portable potentiostat and mass-producible & disposable sampling sensors.
The process involves collecting a blood sample with Fepod’s patented sensor, which is then inserted into a portable potentiostat connected to a mobile phone. The results of the sample are available almost immediately and transferred securely to Fepod’s servers for analysis. Fepod’s servers leverage powerful machine learning technology to process the results and return the analysis to the user.
KEY CUSTOMERS AND INTERNATIONAL PRESENCE
Fepod’s key customers are companies working in the diagnostics segment. Until now Fepod has exclusively been involved in early stage clinical trials within the EU, but are looking to expand their operations into the US and Asia in the coming 6-18 months.
Team
Fepod’s team consists of a three-person core team, with experience from across the healthtech industry. The operational qualifications of Fepod’s core team in the business operations is supplemented with the use of experienced advisors and committed manufactures for their sensors and potentiostats.
Unique selling point
Fepod’s unique technology makes it possible to get fast and quantitative results directly at the point-of-care on substances that no other current rapid testing can handle. Utilizing Fepod’s solution provides healthcare professionals with the ability to improve patient care directly.
Asia Connection
Fepod does not currently have any business operations in Asia, but is looking for partners in the IVD market, potential customers and partners for R&D cooperation in drug research, and interested investors for their upcoming Series A round.
